Bridgebio Pharma Inc (BBIO) - News Archive

: BridgeBio Pharma, Inc. is set to reveal the Phase 3 results of their promising candidate, Encaleret, for treating autosomal dominant hypocalcemia type 1 (ADH1). As the anticipation builds, the pharmaceutical industry...

: The management of Autosomal Dominant Hypocalcemia Type 1 (ADH1), a rare genetic disorder characterized by hypoparathyroidism and associated calcium and magnesium imbalances, has been challenging. Recent developments i...

In the ever-evolving landscape of biopharmaceuticals targeting genetic diseases, BridgeBio Pharma, Inc. stands out as a company committed to advancing treatment options for conditions associated with transthyretin (TTR)...

BridgeBio Pharma Elevates Talent Acquisition with Inducement Grants Amidst Unprecedented Revenue Growth In a significant move to bolster its workforce and fuel its mission to combat genetic diseases, BridgeBio Pharma, I...

Hypoparathyroidism, particularly following surgical interventions, presents a significant challenge in managing calcium homeostasis in patients. Traditional therapies often fail to achieve appropriate normalization of b...

BridgeBio Pharma: Navigating the Dichotomy of Rising Demand and Pertinent Financial LossesIn the realm of biotechnology, where innovation is as commendable as it is hazardous, BridgeBio Pharma Inc. stands at a crossroad...

In the ever-evolving landscape of biopharmaceuticals, the emergence of innovative treatments for genetic diseases offers hope to countless individuals and families grappling with serious medical challenges. BridgeBio Ph...

In a groundbreaking development in the field of cardiology, the U.S. Food and Drug Administration (FDA) has officially approved Attruby (acoramidis), marking a significant milestone in the treatment of patients sufferin...

Breakthrough in Achondroplasia Treatment: BridgeBio s Infigratinib Excels in Phase 2 PROPEL 2 Study While Revenues SurgeBridgeBio Pharma, a prominent figure in the biotechnology arena, has marked a significant milestone...

In a notable advancement within the intersection of finance and biotechnology, BridgeBio Pharma has announced the publication of a compelling case study exploring the implications of portfolio theory on biomedical innov...

BridgeBio Pharma, Inc. a biopharmaceutical company headquartered in Palo Alto, California, has announced its plans to present outcomes data from its ongoing open-label extension of the ATTRibute-CM study, which evaluate...

BridgeBio s FORTIFY Study: A New Hope for LGMD2I/R9 Patients as Enrollment ConcludesBridgeBio Pharma Inc. recently announced the successful completion of patient enrollment in its FORTIFY Phase 3 registrational study of...

BridgeBio Presents Promising Data from ATTRibute-CM Study: Acoramidis Shows Significant Reduction in Mortality and Hospitalizations CSIMarket.com Recent findings from BridgeBio Pharma shed light on the potential of Acor...

BridgeBio Pharma Approves Inducement Grants for New Employees under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif. Sept. 06, 2024 - BridgeBio Pharma, Inc. (Nasdaq: BBIO), a leading biopharmaceutical company focused on...

BridgeBio to Unveil Key Data on Acoramidis for ATTR-CM at ESC Congress 2024 and HFSA Annual Meeting 2024 PALO ALTO, Calif. , Aug. 29, 2024 - BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical co...

BridgeBio Collaboration with CarDS Lab to Enhance Early Diagnosis of Transthyretin Amyloid Cardiomyopathy via Advanced Multimodal Artificial IntelligenceIn the distinguished arena of pharmaceutical sciences, a notable a...

Navigating Achondroplasia: BridgeBio Launches MyAchonJourney, a Vital Resource for Families PALO ALTO, Calif., Aug. 19, 2024 - In a significant move to support families and individuals affected by achondroplasia, Bridge...

BridgeBio Pharma Announces Multiple Equity Grants for New Employees in 2024BridgeBio Pharma, a leading biopharmaceutical company focused on genetic diseases, has recently made significant equity grants to new employees...

BridgeBio Pharma Approves Equity Grants and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif., July 05, 2024 - BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on gene...

BridgeBio Pharma, a company known for its prowess in genetic medicine, has reached a significant milestone in the quest for effective treatments for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). Recently, the c...